74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Editas Medicine Inc
Closed
SectorHealthcare
3 3.45
Overview
Share price change
24h
Min
2.9
Max
3.08
Income | 19M -5.6M |
|---|---|
Sales | 17M 25M |
EPS | -0.06 |
Profit margin | -22.715 |
Employees | 87 |
EBITDA | 17M -5.3M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +145.52% upside |
Next Earnings | 11 May 2026 |
|---|
Market Cap | 56M 283M |
|---|---|
Previous open | -0.45 |
Previous close | 3 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Editas Medicine Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Editas Medicine Inc Forecast
Price Target
By TipRanks
145.52% upside
12 Months Forecast
Average 7.12 USD 145.52%
High 15 USD
Low 4 USD
Based on 8 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Live chat